Navigation Links
Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Date:11/10/2009

ations (1,621,205) (4,282,886) (2,376,061) (3,768,888) Income (loss) from discontinued operations 95,576 (1,868,629) 95,576 (1,868,629) Gain on sale of business unit 6,408,603 - 6,408,603 - ========= === ========= === Net Income (loss) $4,882,974 $(6,151,515) $4,128,118 $(5,637,517) ========== =========== ========== =========== Net loss per common share - basic $0.10 $(0.13) $0.09 $(0.12) ===== ====== ===== ====== Net loss per common share - diluted $0.10 $(0.13) $0.08 $(0.12) ===== ====== ===== ====== Weighted average common shares outstanding - basic 47,771,609 46,603,700 47,771,609 46,603,700 Weighted average common shares outstanding - diluted 49,629,079 46,603,700 49,629,079 46,603,700

                                Nine Months Ended September 30,
                                         (Unaudited)
                          GAAP Financials            Non-GAAP Proforma
                          ---------------            -----------------
                        2009         2008       Pro forma        Pro forma
                      Actual        Actual     Results 2009*    Results 2008*
                      ------        ------     -------------    -------------
    Revenues         $261,549      $374,633     $261,549         $374,633
                     --------      --------     --------         --------
    Research and
     development   (3,528,249)   (9,032,104)  (3,340,256) (1)  (8,292,846) (1)
    Selling,
     general
     and
     adminis-
     trative       (3,819,473)   (4,939,281
'/>"/>
SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
9. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
10. Cardium Launches New AWARE Clinical Study Website
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... After litigating and negotiating patent infringement ... P2i United States patent RE43,651 (the ... the United States without any admission or ... party. As a result of the parties, settlement, the US ... dismissed the case without prejudice. Under ...
(Date:8/25/2015)... ... August 25, 2015 , ... A new ... cancerous is described by University of Illinois researchers in the Journal of ... , In “ Breast cancer diagnosis using spatial light interference microscopy ,” published ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... note: Recently the Wisconsin Technology Network sat down ... Technology Council , to discuss the basic tenants and ... Wisconsins technology space grow. This is the first portion ... faces and how the Wisconsin Technology Council is working ...
... Sonic Foundry Inc . has introduced two ... distribute rich media for a variety of uses. ... real-time, rich media technology, are intended to enable ... needed for corporate communications, Web-based education, online training, ...
... Camtronics Medical Systems has announced that its ... with six terabytes of storage for digital cardiovascular images ... about two years worth of study results, which clinicians ... hospital or over the Web from outreach clinics. In ...
Cached Biology Technology:WTN exclusive interview with Tom Still, Wisconsin Technology Council 2WTN exclusive interview with Tom Still, Wisconsin Technology Council 3WTN exclusive interview with Tom Still, Wisconsin Technology Council 4WTN exclusive interview with Tom Still, Wisconsin Technology Council 5Sonic Foundry announces new Mediasite products 2
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... (April 6, 2009) Cell Press, an imprint of Elsevier, ... well as Current Biology and The American ... Library Association,s (SLA) Top 100 Journals in Biology and Medicine ... compiled by the 680-plus members of the SLA,s Biomedical and ...
... experimental vaccine that triggers the patient,s immune system to ... promise for the treatment of early lung cancer. ... the vaccine called MAGE-A3 Antigen-Specific Cancer Immunotherapeutic, which is ... Rush is one of only five hospitals in Illinois ...
... systems for splitting water into hydrogen and oxygen, driven ... science today, underpinning the long term potential of hydrogen ... exist today are very inefficient and often require additional ... is important to establish new mechanisms by which water ...
Cached Biology News:3 prominent Cell Press journals named among the 100 most influential journals in past 100 years 2Novel lung cancer vaccine shows promise in fighting early-stage lung cancer 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 3
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Biology Products: